NCT04560270 is a NA clinical trial of Blood samples in Pancreatic Cancer, sponsored by Poitiers University Hospital.

Who is sponsoring NCT04560270?

NCT04560270 is sponsored by Poitiers University Hospital.

What drugs are being tested in NCT04560270?

Interventions in NCT04560270: Blood samples.

What condition does NCT04560270 study?

NCT04560270 studies Pancreatic Cancer, Circulating Tumor DNA, KRAS Mutation-Related Tumors.

Is NCT04560270 still recruiting?

NCT04560270 is currently completed. Last updated 23 September 2020.

Last reviewed 2020-09-23 · How we verify

NCT04560270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

Completed NA Last updated 23 September 2020

What this trial tests

NA trial testing Blood samples in Pancreatic Cancer in 69 participants. Completed in 15 November 2019.

Timeline

25 April 2016

Primary endpoint
28 June 2019

15 November 2019

Quick facts

Lead sponsor	Poitiers University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	69
Start date	25 April 2016
Primary completion	28 June 2019
Estimated completion	15 November 2019

Drugs / interventions tested

Blood samples — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Circulating Tumor DNA — all drugs for Circulating Tumor DNA →
KRAS Mutation-Related Tumors — all drugs for KRAS Mutation-Related Tumors →

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with Pancreatic Cancer or Circulating Tumor DNA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem. The aim of this study is to assess the predictive value of response to the 1st line of chemotherapy of mutated KRAS ctDNA (circulating tumor DNA) in unresectable metastatic or locally advanced pancreatic adenocarcinomas.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
Evrard C, Ingrand P, Rochelle T, Martel M, et al · · 2023 · cited 14× · PMID 37308396 · DOI 10.1016/j.dld.2023.03.011
Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma.
Topham JT, Renouf DJ, Schaeffer DF. · · 2023 · cited 9× · PMID 36895849 · DOI 10.1177/17588359231157651

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

NCT07460700 — Mesenteric Ischemia Markers Study · NA · recruiting
NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06694363 — New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome · recruiting
NCT06826066 — Involvement of the Immune System in Intrinsic Radiosensitivity · NA · recruiting
NCT06864481 — Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis · recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Poitiers University Hospital trials

Trials by the same sponsor.

NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04560270 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
Last refreshed: 23 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04560270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing